HK Stock Market Move | CANSINOBIO (06185) rose over 8% intraday, following a prior strategic collaboration with Dopeptide Biotech on mRNA therapeutic tumor vaccines.

CANSINOBIO (06185) rose over 8% intraday, up 6.46% as of press time, at HK$31.3, with a turnover of HK$172 million. On the news front, last month, CANSINOBIO announced that its subsidiary CanSino Biologics Inc. Shanghai and Dopeptide Biotech officially signed the "Strategic Cooperation Framework Agreement for the Co-development of mRNA Personalized Therapeutic Tumor Vaccines." The two parties will leverage their respective strengths in mRNA vaccine technology and tumor neoantigen discovery and design to jointly advance the R&D and commercialization of mRNA personalized therapeutic tumor vaccines. This collaboration is global in scope, focusing on the treatment of gastrointestinal solid tumors and rare tumors, covering stages including early-stage R&D, clinical translation, regulatory filing, and commercialization. It is worth noting that Moderna, a major vaccine concept stock in the U.S. market, has seen its share price continue to climb over the past two days. The company announced that abstracts from three studies of its investigational individualized mRNA neoantigen therapy intismeran autogene, jointly developed with Merck, have been accepted for presentation at the 2026 European Society for Medical Oncology (ESMO) Congress, to be held in Madrid from October 23 to 27. The market believes that as Moderna's personalized tumor mRNA vaccine achieves positive results in Phase III clinical trials, mRNA tumor vaccines are advancing toward the commercialization stage, and the market space is expected to gradually open up.